Amneal’s IPX-203 Increases ‘Good’ ON Time For Parkinson’s Patients

OFF Time Was Reduced With Longer-Acting Levodopa Product

 
• By Mandy Jackson
  
Notebook with PARKINSON'S DISEASE on white wooden background
IPX-203 could be a bigger seller than Amneal's legacy extended-release drug Rytary • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D